Evidence map›Paper›PMID 42359646›Full record

ArticleMolecular medicine reports2026

Regulatory function of ten‑eleven translocation‑2 in transcriptional mechanisms of demethylated myeloma cells.

Lenka Slavickova, Michaela Nemcova, Dominika Svehlova, Veronika Frybortova, Jirina Manakova, Eva Kriegova, Jiri Minarik, Katerina Smesny Trtkova

Abstract read
In one paragraph

Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lenka SlavickovaDepartment of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic.
Michaela NemcovaDepartment of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic.
Dominika SvehlovaDepartment of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic.
Veronika FrybortovaDepartment of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic.
Jirina ManakovaDepartment of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic.
Eva KriegovaDepartment of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic.
Jiri MinarikDepartment of Hemato‑Oncology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic.
Katerina Smesny TrtkovaDepartment of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is a malignant plasma cell disorder characterized by clonal expansion of plasma cells in bone marrow. Genetic aberrations in MM are well‑established, while epigenetic alterations, particularly DNA methylation, are increasingly recognized as key regulators of gene expression. The modified bases 5‑methylcytosine (5‑mC) and 5‑hydroxymethylcytosine (5‑hmC) occur in gene promoters and regulatory regions. While the presence of 5‑mC in the promoter is associated with transcriptional silencing, 5‑hmC, generated by oxidation of 5‑mC through ten‑eleven translocation (TET), is associated with gene activation. The present study investigated promoter‑specific 5‑hmC and 5‑mC levels in

Indexed as

DioxygenasesDNA-Binding ProteinsDNA MethylationMixed Function OxygenasesMultiple MyelomaProto-Oncogene ProteinsTranscription, Genetic5-MethylcytosineAgedAzacitidineCell Line, TumorEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHumansMiddle Aged5-hydroxymethylcytosine5-MethylcytosineAzacitidineDioxygenasesDNA-Binding ProteinsMixed Function OxygenasesProto-Oncogene ProteinsSp1 Transcription FactorSP3 protein, humanSp3 Transcription FactorTET1 protein, humanTET2 protein, humanTET3 protein, humandemethylating agentsdemethylationmultiple myelomaspecificity protein transcription factorsten‑eleven translocation genes

Identifiers

PMID42359646
PMCPMC13343343

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.